Opinion|Videos|August 13, 2024
Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment
In this discussion, panelists explore the potential role of new Bruton tyrosine kinase inhibitors in the treatment landscape for chronic spontaneous urticaria (CSU), evaluating their stages of development and expected impact on treatment algorithms, while also considering future changes in coverage and payer strategies with the emergence of new therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Where do you see certain prescriptions fitting into treatment algorithms for patients living with chronic spontaneous urticaria (CSU)?
a. Given the data you’ve seen to date, how would you advise managed
- Another Bruton tyrosine kinase inhibitor, rilzabrutinib, is also under investigation for patients living with CSU. What stage of development is this molecule in and what has the data demonstrated?
- How do you see treatment algorithms changing in the future with the introduction of newer classes of therapies?
a. With potential new treatment options on the horizon, how do you think payers should anticipate covering CSU in the next few years?
Advertisement
Related to this article
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.
Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
3
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
4
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
5